Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate ...
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling ...